Affinity Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Affinity Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-27,260	Closed	-$458K	–	141
2023 Q4	$458K	Sell	27,260 -21,480	-44%	-$294K	0.31%	102
2023 Q3	$570K	Sell	48,740 -690	-1%	-$9.23K	0.37%	100
2023 Q2	$664K	Sell	49,430 -16,604	-25%	-$239K	0.38%	97
2023 Q1	$1.09M	Sell	66,034 -143	-0.2%	-$2.36K	0.59%	51
2022 Q4	$1.23M	Sell	66,177 -24,687	-27%	-$380K	0.57%	50
2022 Q3	$1.17M	Hold	90,864	–	–	0.61%	46
2022 Q2	$637K	Hold	90,864	–	–	0.31%	109
2022 Q1	$753K	Buy	+90,864	New	+$642K	0.31%	124

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Affinity Investment Advisors's CPRX Position: Q1 2024 in Review

Affinity Investment Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 27,260 shares — an estimated $458K sold.

Affinity Investment Advisors first reported a position in CPRX in Q1 2022 and held it in 8 quarters. The position peaked at $1.23M in Q4 2022. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

Affinity Investment Advisors reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
Affinity Investment Advisors sold 27,260 Catalyst Pharmaceutical shares in Q1 2024, an estimated $458K.
Affinity Investment Advisors first reported a position in Catalyst Pharmaceutical in Q1 2022 and held it in 8 quarters.
Affinity Investment Advisors's Catalyst Pharmaceutical position peaked at $1.23M in Q4 2022.
269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Affinity Investment Advisors's 13F filing for Q1 2024, filed 3 May 2024.